Enveric Biosciences (ENVB) Non-Current Deferred Tax Liability (2021 - 2022)
Enveric Biosciences (ENVB) posted Non-Current Deferred Tax Liability of $1.5 million for Q3 2022, down 8.84% sequentially from $1.6 million in Q2 2022.
Enveric Biosciences (ENVB) Non-Current Deferred Tax Liability (2021 - 2022) Analysis & Trends
Enveric Biosciences has reported Non-Current Deferred Tax Liability for 2 years, with the latest figure at $1.5 million in Q3 2022.
- Quarterly Non-Current Deferred Tax Liability changed N/A year-over-year to $1.5 million in Q3 2022, while the trailing twelve-month figure through Sep 2022 was $1.5 million (changed N/A YoY) and the FY2021 annual result came in at $1.6 million, changed N/A from the prior year.
- Non-Current Deferred Tax Liability slipped to $1.5 million in Q3 2022 per ENVB's latest filing, from $1.6 million in the prior quarter.
- Over five years, Non-Current Deferred Tax Liability peaked at $1.6 million in Q1 2022 and troughed at $1.5 million in Q3 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - |
| 10 | Enveric Biosciences | 5.58 Mn | -2.71 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2022 | 1.49 Mn |
| Sep 30, 2022 | 1.49 Mn |
| Jun 30, 2022 | 1.63 Mn |
| Jun 30, 2022 | 1.63 Mn |
| Mar 31, 2022 | 1.63 Mn |
| Mar 31, 2022 | 1.63 Mn |
| Dec 31, 2021 | 1.61 Mn |
| Dec 31, 2021 | 1.61 Mn |